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Abstract
Background: Guidelines recommend the use of multiple pharmacologic agents and/or mechanical compressive devices for
prevention of venous thromboembolism, but preference for any specific agent is no longer given in regard to safety or efficacy.
Objective: To compare postoperative bleeding rates in patients receiving enoxaparin, rivaroxaban, or aspirin for thromboprophylaxis after undergoing elective total hip arthroplasty or total knee arthroplasty. Methods: This retrospective cohort
analysis evaluated patients who received thromboprophylaxis with either enoxaparin, rivaroxaban, or aspirin. All data were
collected from the electronic medical record. The primary outcome was any postoperative bleeding. Results: A total of 1244
patients were included with 366 in the aspirin, 438 in the enoxaparin, and 440 in the rivaroxaban arms. Those who received aspirin
or enoxaparin were less likely to experience any bleeding compared to those patients who received rivaroxaban (P < .05). There
was also a lower rate of major bleeding in these groups, but the differences were not significant. Conclusions: Aspirin and
enoxaparin conferred similar bleeding risks, and both exhibited less bleeding than patients who received rivaroxaban.
Keywords
venous thromboembolism, rivaroxaban, enoxaparin, aspirin, deep vein thrombosis, pulmonary embolism, total hip arthroplasty,
total knee arthroplasty, prophylaxis

Introduction
Total hip arthroplasty (THA) and total knee arthroplasty (TKA)
occur frequently, with about 300 000 THA surgeries and more
than 500 000 TKA surgeries performed annually in the United
States.1 This number is projected to rise to almost 600 000
annual THA surgeries and 3.5 million annual TKA surgeries
by 2030.1 Patients undergoing these procedures are at a significantly increased risk of developing postoperative complications, most notably venous thromboembolism (VTE).2,3 The
incidence of VTE after THA or TKA is reduced by the use
of thromboprophylactics, such as vitamin K antagonists,
unfractionated heparin (UFH), low-molecular-weight heparin
(LMWH), direct oral anticoagulants (DOACs), or aspirin
(ASA).3 However, these medications have a number of limitations that impede their use, including increased bleeding risk.
The potential for bleeding secondary to prophylaxis has been
associated with prolonged recovery, infections, wound failure,

and readmission.4 Therefore, the risk versus benefit is a primary consideration when a provider chooses VTE prophylaxis
in these patients.
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Prior to the 2012 update to the American College of Chest
Physicians (ACCP) guidelines,3 LMWH and warfarin were
the commonly used options for VTE prophylaxis in THA and
TKA patients in the United States.5 In 2008 to 2009, the
Regulation of Coagulation in Orthopedic Surgery to Prevent
Deep Vein Thrombosis and Pulmonary Embolism (RECORD)
1 to 4 trials were published, which compared oral rivaroxaban
10 mg daily to enoxaparin (either 30 mg every 12 hours
[q12h] or 40 mg q24h) for the prevention of VTE in THA
and TKA patients.6-9 Rivaroxaban was approved for this indication in the United States in 2011 as these trials showed
similar rates of VTE with similar bleeding rates. Trials with
other oral anticoagulants, including apixaban and dabigatran,
also demonstrated similar efficacy with similar or decreased
rates of major and minor bleeding.10-15
The arrival of the DOACs, the 2012 ACCP guideline
update, the long-standing endorsement of other therapies, such
as ASA, by the American Association of Orthopaedic Surgeons,16 and other factors, such as broader specialty representation on ACCP committees, created opportunity for a
paradigm shift in the interpretation of existing evidence. This
broadened the options that were guideline endorsed, allowing
providers even more options to manage thrombosis risk postsurgery. Although consensus was reached, debate still exists
regarding ASA as evidenced by the statement in the ACCP
guidelines, including a statement that read, “one panel member
believed strongly that ASA alone should not be included as an
option.”3(pe295S) The addition of ASA as a recommended option
only broadened the number of opinions.17,18
The appeal of ASA is likely the low cost coupled with the
perception that bleeding risk is lower compared to traditional
anticoagulants. There is mixed evidence in regard to the safety
and efficacy of ASA when compared to other agents.5,19-21
Complicating this decision further is the trade-off of risk and
benefit as clinicians should be cautious because choosing a
perceived lower risk with 1 agent may increase the risk of a
preventable harmful outcome with another. Previous studies
showed similar rates of major bleeding between ASA, UFH,
LMWH, and warfarin.20,21 A study by Brown was able to show
that ASA was associated with lower operative site bleeding
events compared to LMWH (P < .0001), with no significant
difference observed in total bleeding.22 In addition, a multivariate analysis showed that ASA was an independent predictor
of decreased costs for these surgeries, mainly attributed to a
shorter length of initial hospitalization.23 However, a more
recent network meta-analysis calls into question the assumption that ASA has lower or similar bleeding rates due to the
paucity of methodologically sound data.24 Furthermore, those
authors call into question contemporary guidelines, including
the ACCP guidelines, which offer no clear preferential recommendations regarding particular agents other than 2B or 2C
recommendations of “preference” favoring more traditional
LMWH over other options, including ASA. Furthermore, no
clear guidance on risk stratification is provided, ultimately
leaving the decision of risk versus benefit to the subjective
discretion of the provider.
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The recently published Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II (EPCAT II) data add an
additional layer to this complex question in that they evaluated
a combination regimen that included both rivaroxaban for 6
days followed by low-dose (81 mg) ASA versus a traditional
rivaroxaban regimen of 10 mg daily.25 Although this does support the hypothesis that ASA is an effective chemoprophylactic
option, the possibility still exists that higher dosed ASA regimens, without lead-in potent anticoagulation, could be still be
less efficacious or carry a higher safety risk or both. One editorialist points out that the EPCAT II data also failed to evaluate any additive benefit of mechanical prophylaxis, which was
utilized in only about 15% of trial participants.26
In 2014, a study at our institution compared a local cohort
of patients who received rivaroxaban to the historical
RECORD trials and observed a statistically significant
increase in “real-world” bleeding events.27 In order to evaluate whether this outcome was valid, we compared a local
enoxaparin group to the historical enoxaparin groups in the
RECORD trials and then also to the local rivaroxaban
patients.28 This study found increased bleeding in the local
rivaroxaban patients compared to that in local enoxaparin,
while similar bleeding rates existed between the local and
historical enoxaparin patients. To further assess the safety
of utilizing ASA for thromboprophylaxis in a similar patient
population, the purpose of this study was to compare postoperative bleeding rates in patients receiving ASA to patients
who received enoxaparin or rivaroxaban after undergoing
elective THA or TKA.

Methods
This was a retrospective study approved by the local institutional review board. This study collected patient information
from 2 regional institutions within 1 local health-care system.
Both institutions are designated as Orthopedic Centers of
Excellence. One institution is a 261-bed community hospital
that performs approximately 100 THA and 200 TKA surgeries
annually. The other institution is a 488-bed community teaching facility that performs approximately 250 THA and 400
TKA surgeries annually. Patients admitted to either of the 2
study institutions between January 1, 2012, and January 25,
2016, were screened for inclusion in the study.
The study population consisted of patients who were 18 years
or older, underwent elective THA or TKA, and received ASA,
enoxaparin, or rivaroxaban for postoperative thromboprophylaxis. Dosages of VTE prophylaxis were as follows: ASA orally
325 mg 2 times a day, rivaroxaban 10 mg orally daily for creatinine clearance (CrCl) >30 mL/min, and enoxaparin subcutaneously either 30 mg q12h or 40 mg q24h for CrCl >30 mL/min
or 30 mg q24h if CrCl <30 mL/min. The dosage of enoxaparin
was at the discretion of the treating physician, but the order set
recommended 30 mg q12h (CrCl >30 mL/min) for this patient
population. Duration of VTE prophylaxis was determined by the
treating physician; however, all VTE prophylaxis regimens are
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Table 1. Baseline Demographics and Hospital Length of Stay.
Variable
Age in years, mean (range)
Female (%)
Caucasian (%)
Weight in kg, mean (range)
THA (%)
TKA (%)
SCr in mg/dL, mean (range)
Hgb in g/dL, mean (range)
Length of stay in days, mean (range)

Aspirin, n ¼ 366
65.8
223
366
87.9
188
178
0.8
11.2
2.0

(30-92)
(60.9)
(100.0)
(46-155)
(51.4)
(48.6)
(0.3-1.7)
(5.7-15.3)
(1-10)

Enoxaparin, n ¼ 438
66.7 (35-91)
289 (66.0)
343 (99.1)
90.6 (36-154)
141 (32.2)
297 (67.8)
1.0 (0.3-3.0)
10.5 (6.6-15.1)
4.6 (2-15)

Rivaroxaban, n ¼ 440
65.4
285
415
89.1
167
273
0.9
10.6
3.6

(29-93)
(64.8)
(94.3)
(37-173)
(38.0)
(62.0)
(0.5-2.2)
(6.0-15.1)
(1-16)

P Value
.08
.308
<.001
.178
<.001
<.001
<.001
<.001
<.001

Abbreviations: Hgb, hemoglobin; SCr, serum creatinine; THA, total hip arthroplasty; TKA, total knee arthroplasty.

ordered via standardized order sets with suggested durations of
12 and 35 days for TKA and THA, respectively. Patients were
excluded if they were diagnosed with active bleeding prior to
surgery, received another anticoagulant for greater than 24
hours, were admitted directly to the intensive care unit, had an
international normalized ratio of greater than 1.5 on the day of
surgery, had an estimated CrCl of less than 30 mL/min, or
received concomitant protease inhibitor therapy.
The primary outcome was any postoperative bleeding. This
was defined as a composite of clinically overt fatal bleeding,
critical organ bleeding, bleeding requiring the transfusion of
2 or more units of blood, bleeding that necessitated operation,
and bleeding outside the surgical site that was associated with a
hemoglobin (Hgb) decrease of 2 g/dL, and clinically relevant
nonmajor bleeding (CRNMB). The outcome of CRNMB was
defined consistent with the RECORD trials and included multiple source bleeding events, unexpected hematoma, excessive
wound hematoma, nose bleeding, vaginal/semen bleeding, surgical site bleeding, gingival bleeding, macroscopic hematuria,
rectal bleeding, coughing or vomiting blood, or intraarticular
bleeding with trauma. Secondary outcomes included individual
components of the primary outcome, as well as the receipt of
blood transfusions and rate of 30-day readmissions for any
reason. Baseline demographics collected were age, sex, race,
weight, type of operation, baseline serum creatinine (SCr), preand postoperative Hgb, and length of stay.
To achieve 80% power using a 2-sided a value of .05, assuming a 5% absolute difference as being clinically relevant, it was
determined that 435 patients per group would be required.
Categorical variables were analyzed with a logistic regression
analysis. A w2 or Fisher exact test was used for categorical demographic data as appropriate. An analysis of variance (ANOVA)
with post hoc tests was used for continuous data. All analyses
were performed using SPSS software, version 23 (IBM Corporation, New York, New York). All reported P values were 2 sided,
with a value of less than .05 considered statistically significant.

Results
A total of 1244 patients were included in the final analysis, with
366 patients receiving ASA. These patients were compared to
the 2 cohorts of patients previously identified who had received

rivaroxaban (440) and enoxaparin (438). Complete baseline
demographics are listed in Table 1. The mean age of the ASA,
rivaroxaban, and enoxaparin groups was 65.4, 66.7, and 65.8
years, respectively. The majority of patients were female in all
groups and almost all were Caucasian. The ASA group was
relatively even in the number of THAs versus TKAs. Baseline
SCr and Hgb differed minimally between groups, and these
differences were not thought to be clinically meaningful.
Patients who received ASA had shorter hospital length of stay
when compared to patients who received enoxaparin or rivaroxaban (P < .001).
The results of this study can be found in Table 2. Based on a
logistic regression analysis of the 3 independent groups,
patients who received rivaroxaban were twice as likely to experience any bleeding compared to those patients who received
ASA therapy (odds ratio [OR]: 2.19, 95% confidence interval
[CI]: 1.07-4.46). There was a similar rate of major bleeding in
the ASA and enoxaparin groups. Despite higher rates of major
bleeding in the rivaroxaban group (OR ¼ 5.05, 95% CI: 0.6142.1), the difference was not significant. No other differences
were detected between the 3 treatments in regard to outcomes
associated with bleeding.
The number of patients requiring blood transfusions was elevated in both the enoxaparin and rivaroxaban groups compared
to those who received ASA; however, this was likely due to a
change in practice versus an increased rate of bleeding events. A
1-way ANOVA with post hoc analyses indicated that length of
stay was significantly different between each of the 3 study
groups with the shortest length of stay, in days, being associated
with ASA (mean ¼ 2.0), followed by rivaroxaban (mean ¼ 3.6)
and lastly enoxaparin (mean ¼ 4.6), with a P value <.001 for all
comparisons. Patients were 3.7 (95% CI: 1.8-7.7) times more
likely to be readmitted within 30 days when taking ASA compared to enoxaparin. No difference in 30-day readmission rates
existed between the ASA and rivaroxaban groups (Table 3).
Reason for readmission was not collected in patients receiving rivaroxaban; however, for those receiving enoxaparin,
2 patients were readmitted for an infected joint, 1 to rule out
VTE, and none were readmitted for bleeding complications.
In the ASA group, 5 patients were admitted for an infected
joint, 5 to rule out VTE, and 3 for bleeding, with 2 of those
being listed as a gastrointestinal bleed.
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Table 2. Bleeding Outcomes for Patients Who Received Enoxaparin and Rivaroxaban Relative to Those Who Received Aspirin Therapy.
Aspirin, n ¼ 366, Enoxaparin, n ¼ 438,
n (%)
n (%)

Variable
Any bleedinga
Major bleeding
Bleeding into a critical organ
Bleeding leading to reoperation
Clinically overt bleeding ! decreased
hemoglobin
Clinically overt bleeding ! transfusion
2 units
Clinically relevant nonmajor bleeding
Receipt of blood transfusions

11 (3.3)
1 (0.3)
0 (0)
0 (0)
0 (0)

10
1
1
0
0

(2.2)
(0.2)
(0.2)
(0)
(0)

OR (95% CI)
0.75 (0.32-1.79)
0.84 (0.05-13.4)
–
–
–

Rivaroxaban n ¼ 440,
n (%)
30
6
0
3
3

(6.8)
(1.4)
(0)
(0.7)
(0.7)

OR (95% CI)
2.19 (1.07-4.46)
5.05 (0.61-42.1)
–
–
–

1 (0.3)

0 (0)

–

3 (0.7)

2.51 (0.26-24.19)

10 (3.0)
19 (5.2)

9 (2.1)
158 (36.1)

0.75 (0.3-1.86)
10.3 (6.2-17.0)

24 (5.5)
111 (25.2)

2.1 (0.97-4.35)
6.2 (3.7-10.3)

Abbreviations: CI, confidence interval; OR, odds ratio.
a
Defined as clinically relevant nonmajor bleeding plus major bleeding.

Table 3. Thirty-Day Readmission Rates for Patients Who Received Enoxaparin and Rivaroxaban Relative to Those Who Received Aspirin.
Variable
30-day readmissions

Aspirin, n ¼ 366, n (%) Enoxaparin, n ¼ 438, n (%)
29 (8.0)

10 (2.3)

OR (95% CI)

Rivaroxaban, n ¼ 440, n (%)

OR (95% CI)

0.27 (0.13-0.56)

28 (6.4)

0.79 (0.46-1.35)

Abbreviations: CI, confidence interval; OR, odds ratio.

Discussion
Any postoperative bleeding, defined in this study as a composite
of clinically overt fatal bleeding, critical organ bleeding, bleeding
requiring transfusion of 2 or more units of blood, bleeding that
necessitated reoperation, bleeding outside the surgical site that
was associated with a Hgb decrease in 2 g/dL, or CRNMB, was
lower in the ASA group compared to those who received rivaroxaban but similar to those patients who received enoxaparin. The
absolute difference in these bleeding rates, as the primary composite outcome, was 3.5% (3.3% for ASA vs 6.8% for rivaroxaban), resulting in a number-needed-to-harm of 29. Most would
consider this to hold clinical significance; however, any potential
harm would have to be weighed against potential benefit.
Major bleeding rates alone were low overall at 0.3% for ASA,
0.2% for enoxaparin, and 1.4% for rivaroxaban patients. The
numeric difference between ASA and enoxaparin compared to
rivaroxaban was lower but not significant; however, this trial was
not powered to detect differences in major bleeding rates alone.
Additionally, this trial did not assess efficacy outcomes, and to
our knowledge, no direct comparisons between rivaroxaban and
ASA for efficacy exist for orthopedic VTE prophylaxis.
Interestingly though, both rivaroxaban and apixaban have
been shown to be more efficacious than ASA without an
increased risk of bleeding in 2 different patient populations.29,30 In the Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or
Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) study, which included patients with atrial fibrillation
deemed inappropriate candidates for warfarin therapy, those
who received low-dose apixaban had improved efficacy outcomes, specifically stroke and systemic embolization, without

an observed increased risk in bleeding outcomes.29 In the
Reduced-dosed Rivaroxaban in the Long-term Prevention of
Recurrent Symptomatic Venous Thromboembolism (EINSTEIN CHOICE) study, which evaluated the long-term prevention of VTE, rivaroxaban at both 20 mg and 10 mg daily
conferred a lower risk of developing fatal or nonfatal VTE than
did ASA with a similar risk of major bleeding.30
The decision of the best VTE prophylactic agent in the highrisk orthopedic population is also confounded by the differences of opinion between those providers who emphasize
prevention of VTE over nonmajor bleeding events. In fact,
many providers cannot agree on a valid outcome to measure
VTE with historical guidelines including any event along the
gamut from asymptomatic objectively confirmed DVT to fatal
PE, with varying results and opinions from analyses.31,32 A
lack of validated bleeding risk assessments is also a barrier to
clinicians identifying subpopulations who may or may not benefit from a particular therapy, and it is the experience of the
authors that most orthopedic providers use a standardized
approach for all patients without an individualized assessment
and risk stratification, in the absence of such a clinical tool.
These results are also interesting in that between those
patients who received enoxaparin compared to ASA, there was
not an increased risk for bleeding, and in fact, the patients who
received enoxaparin had a lower bleeding rate than those who
received ASA. This finding is consistent with prior studies that
have not found a decreased bleeding risk with ASA compared
to other anticoagulants.20,21 A more recent retrospective database analysis found similar findings relative to transfusions,33
but our data add to this finding in that we also include a comparison to rivaroxaban.
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Of note, the primary contemporary evidence often referenced for ASA in this population are data from the Pulmonary
Embolism Prevention trial.34 There were multiple limitations
in the research methodology, despite the fact it was a large
population. Additionally, it has been demonstrated that ASA
is not benign and that bleeding risk is as much a concern with
ASA, as it is with more traditional anticoagulants.5,35
While efficacy was not a focus of our study, we did observe
more patients in the ASA group being readmitted to rule out
VTE, although none actually had an objective event. This begs
the question of whether or not providers are less confident in
the effects of ASA and have a lower threshold for evaluating
symptoms in patients who have been discharged on an ASA
regimen compared to a more traditional anticoagulant
approach. Additionally, we noted more admissions for wound
infections, which could be directly related to bleeding, in those
patients receiving ASA compared to enoxaparin. Unfortunately, as data collection was done in 3 separate cohorts, reason
for readmission, which was not a primary or secondary endpoint of the study, was not recorded for the rivaroxaban group.
There was a statistically higher rate of blood transfusions in
the rivaroxaban and enoxaparin groups compared with the
ASA group (25.2% vs 36.1% vs 5.2%, P < .05, respectively).
The authors are confident that this could be attributed to a
change in blood transfusion guidelines published in 2012,
which raised the recommended transfusion threshold to an Hgb
value of less than 7 mg/dL.36 The majority of the patients in the
ASA group were included after June 2015, coinciding with a
local practice change, while the historical enoxaparin and rivaroxaban groups included patients as late as August 2011, prior
to the publication of new transfusion guidelines. Given this
confounder, the data regarding blood transfusions are less helpful than the observed event rates.
Our findings differ in that based on our definition, consistent
with other trials, rates of bleeding were not greater with enoxaparin compared to ASA but were higher with rivaroxaban
relative to ASA. We would point out that not all anticoagulants
are the same and that clinicians and investigators alike should
not evaluate all anticoagulants within and between classes
without comparative data, such as these presented here.
One concerning finding was the higher readmission rates in the
cohort of patients who received ASA therapy. This is coupled
with a significantly shorter length of stay for these patients compared to both the enoxaparin and the rivaroxaban cohort. Potential
explanations for this include a paradigm shift in patient care leading to earlier discharge from hospital, a change in dosage formulation from injectable to oral therapies over time, need for patient
education with injectable compared to oral agents, or physician
comfort (or discomfort) with new prophylactic options compared
to historical treatments. Although it is outside the scope of this
publication, one future researchable hypothesis could be whether
or not length of stay for a high-risk orthopedic procedure is truly
inversely related to the likelihood for 30-day readmission as was
observed in this sample of patients.
The limitations of this trial include the limited patient population from 2 community hospitals within a single health-care
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system, as well as potential loss to follow up postsurgery. Variances in surgical techniques and medications that could have
been used in the periprocedural period were not taken into
consideration for the purposes of this study, secondary to limitations within the local electronic medical record. Additionally, due to limitations in the electronic medical record,
information regarding tranexamic acid use was unable to be
retrieved. It is less likely that patients receiving either rivaroxaban or ASA had a difference, but this is an assumption based
on practice patterns given those data are unavailable.
Another limitation is the failure to identify the target of 435
patients for inclusion in the ASA group; however, a difference
was still detected in the primary outcome between the rivaroxaban and ASA groups. Given the small difference between the
enoxaparin and ASA groups (2.2% vs 3.3%, respectively), it is
unlikely that evaluating the additional 80 patients would result
in a significant difference between the groups. Even if one
assumed a doubling of the rate of the primary outcome in those
additional patients, the result would still be insignificant.

Conclusion
Despite these and other published data, it is still not clear that 1
agent is superior in terms of collective efficacy and safety
compared to other recommended agents. This study illustrates
that bleeding risk is present with all 3 classes of thrombophylactics studied and that those patients who received either ASA
or enoxaparin were at similar risks of having a bleeding event
following TKA or THA. Stratifying patients based on known
risks and benefits of bleeding and VTE prophylaxis, respectively, would be an optimal approach, until validated risk stratification systems are available for routine use.
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